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Introduction
Genetic testing for Huntington disease (HD), by direct
analysis of the CAG repeat within the IT-15 gene that
encodes the huntingtin protein, has been performed, for
clinical purposes, since the summer of 1993. HD was
one of the first of what is now a group of “CAG-repeat
disorders” for which direct gene analysis is possible;
these disorders include spinocerebellar ataxia types 1, 2,
3, and 6; Kennedy disease; and dentatorubropallidol-
uysian atrophy (LaSpada et al. 1991; Huntington’s Dis-
ease Collaborative Research Group [HDCRG] 1993;
Orr et al. 1993; Kawaguchi et al. 1994; Koide et al.
1994; Nagafuchi et al. 1994; Imbert et al. 1996; Pulst
et al. 1996; Sanpei et al. 1996; Zhuchenko et al. 1997).
HD remains the most commonly tested CAG-repeat dis-
order in the United States.
At the October 1996 Workshop of U.S. HD Genetic
Testing Centers, held in San Francisco, results of surveys
of clinical centers and laboratories performing genetic
tests for HD were presented. The total number of IT-15
gene tests performed by 15 laboratories (of 26 surveyed)
through mid-1996 was 2,941. Extrapolating from these
figures, we can estimate that ∼4,700 IT-15 gene tests
were performed in the United States from 1993 to mid-
1996. A similar number of IT-15 gene tests have been
reported in the literature (Nance 1996). The need to
standardize the methods and terminology used by clin-
ical laboratories performing these tests was recognized,
which led to the formation, in December 1996, of an
American College of Medical Genetics/American Society
of Human Genetics Huntington Disease Genetic Testing
Working Group. The charge to this groupwas to develop
practice guidelines for the laboratory aspects of genetic
testing for HD. The following recommendations of the
working group are based on a review of the published
literature, the results of the 1996 surveys, and formal
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and informal discussions with representatives of ∼25
laboratories and ∼75 clinical centers involved in HD
genetic testing.
Recommendations
A. Standardization and Interpretation of IT-15 Gene
(CAG)n Repeat Ranges
Both the published literature and unpublished expe-
rience support the definition of four diagnostic catego-
ries for CAG-repeat lengths in exon 1 of the IT-15 gene,
which is shown diagrammatically in figure 1. Labora-
tories should define CAG-repeat ranges as shown below
until additional evidence supports a change or changes
in the definitions. The working group supports the stan-
dardized use of the CAG category descriptors given be-
low. The CAG-repeat ranges and their descriptions are
shown in table 1.
Allele sizes of X26 CAG repeats have never been as-
sociated with an HD phenotype in the U.S. survey or in
any published study. Allele sizes of X26 CAG repeats
have not been demonstrated to showmutability (meiotic
instability that results in an HD allele in offspring)
(HDCRG1993; Duyao et al. 1993; Benjamin et al. 1994;
Kremer et al. 1994). Although it has not been shown
that alleles with X26 repeats cannot be mutable, no
examples of mutable alleles of this size have been re-
ported, to date. The shortest reportedCAG-repeat length
in a human IT-15 gene is nine CAG repeats; there is no
evidence that smaller repeat lengths cannot occur or that
they would lead to an abnormal phenotype.
Allele sizes of 27–35 CAG repeats have not been as-
sociated convincingly with an HD phenotype (Kremer
et al. 1994; Rubinsztein et al. 1996). Alleles of 27–35
CAG repeats have demonstrated meiotic instability in
sperm (Leeflang et al. 1995; Telenius et al. 1995; Chong
et al. 1997). An allele with 27 CAG repeats was reported
in the father of an HD-affected individual with 38 re-
peats (McGlennan et al. 1995), and larger alleles in this
range have also demonstrated mutability when trans-
mitted by a male (see Definitions, below) (Goldberg et
al. 1993; HDCRG 1993; Myers et al. 1993). Approxi-
mately 1.5%–2.0% of alleles reported in the U.S. survey
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Figure 1 Diagram of the IT-15 gene, showing the location of
the CAG-repeat sequence and the boundaries defining the ranges of
normal, mutable normal, HD allele with reduced penetrance, and HD
allele with full penetrance, based on the worldwide published expe-
rience and the experience of the USHuntingtonDiseaseGenetic Testing
Group.
Table 1
CAG-Repeat Length Categories and Descriptors
Category
Description
CAG-Repeat
Range
Predicted
Phenotype
Normal allele X26 Normal
Mutable normal
allele
27–35 Normal
HD allele with re-
duced penetrance
36–39 Normal/HD
HD allele x40 HD
and in the literature have 27–35 repeats (Goldberg et
al. 1995). The biological mechanisms underlyingmeiotic
instability are not known in detail; however, the fre-
quency of CAG-repeat instability in sperm is known to
increase with increasing CAG-repeat number (Zu¨hlke et
al. 1993; Kremer et al. 1995; Leeflang et al. 1995; Te-
lenius et al. 1995). The likelihood that transmission of
an allele in the 27–35-repeat range will result in an HD
allele (mutability) is unknown but depends on how close
the allele size is to the HD threshold as well as on the
frequency and magnitude of expansions, which are de-
pendent on the sex of the transmitting individual and
on other unknown factors. More clinical research is re-
quired before accurate or specific mutability risk figures
can be given to individuals, particularly women, with
allele sizes of 27–35 repeats.
Allele sizes of 36–39 repeats have been associatedwith
the HD phenotype in cases documented clinically (Kre-
mer et al. 1994; Legius et al. 1994; Rubinsztein et al.
1996) and pathologically (Persichetti et al. 1994). Alleles
in this size range are abnormal. However, the HD phe-
notype is not always penetrant in individuals with HD
alleles in this size range. Alleles of 36–39 CAG repeats
have been reported in some clinically unaffected indi-
viduals aged 170 years (Legius et al. 1994; Rubinsztein
et al. 1996; McNeil et al. 1997; U.S. HD Genetic Testing
Group, unpublished data). Empirical penetrance risks
for the HD phenotype at CAG-repeat lengths of 36, 37,
38, and 39 repeats have not been published; ascertain-
ment biases preclude the use of current or published data
for this purpose.
The absence of HD pathology has not been docu-
mented in any individual with an HD allele size of x40
CAG repeats who died, disease-free, after living up to
or past the normal life expectancy. There are, however,
individuals who do not develop symptomatic HD until
the 9th decade and individuals with repeat sizes of x40
who die, disease-free, “prematurely.”
The working group strongly recommends that labo-
ratories uniformly adopt the above-noted ranges and
descriptions in their interpretation of IT-15 gene test re-
sults. Reports should reflect what is currently known
about the tested individual’s risk of developing HD as
well as the risk that the individual’s offspring could have
a similar or larger allele size.
It should be noted that essentially all published data
about IT-15 exon 1 CAG-repeat lengths are based on
studies of lymphocyte DNA and may not reflect allele
sizes in other tissues, such as testis/ovaries, amniocytes,
or the CNS. Limited data suggest that CAG-repeat
lengths are stable in lymphoblasts, chorionic villus tis-
sues, and somatic tissues other than brain (MacDonald
et al. 1993; Zu¨hlke et al. 1993; Benitez et al. 1995).
Mosaicism for CAG-repeat length has been reported in
sperm and in CNS (MacDonald et al. 1993; Telenius et
al. 1994).
B. Definitions
IT-15 gene.—The gene encoding the huntingtin pro-
tein. Abnormal expansion of a polymorphic CAG-repeat
sequence within exon 1 of the IT-15 gene causes
Huntington disease.
HD allele.—An IT-15 gene with x36 CAG repeats in
the polymorphic CAG-repeat region in exon 1. The HD
phenotype is not always penetrant for CAG-repeat sizes
of 36–39 repeats but appears to be fully penetrant for
allele sizes of x40 repeats.
Normal allele.—An IT-15 gene with X35 CAG re-
peats. These alleles do not cause HD. Normal alleles of
any size may exhibit meiotic instability, albeit infre-
quently, but only alleles of 27–35 repeats have been
shown to exhibit mutability (see below).
Meiotic instability.—The ability of an allele to increase
or decrease CAG-repeat length during meiosis, such that
the modal CAG-repeat number present on an IT-15 allele
in an individual’s somatic cells is not the same as the
repeat number(s) present on the same allele in his or her
gametes. Meiotic instability for CAG-repeat length in
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the IT-15 allele has been demonstrated directly by anal-
ysis of sperm DNA (MacDonald et al. 1993; Telenius et
al. 1993, 1995; Goldberg et al. 1995; Chong et al. 1997).
Meiotic instability of trinucleotide repeat sequences has
been demonstrated directly in human oocytes for fragile
X syndrome (Malter et al. 1997) but has only been in-
ferred in HD from the analysis of somatic CAG-repeat
numbers in mother-child pairs (Andrew et al. 1993).
Mutability.—The ability of a normal allele to change
to an HD allele in the next generation. To date, only
normal alleles with CAG-repeat sizes of 27–35 repeats
have been reported to exhibit mutability.
C. Recommendations Regarding Laboratory Standards
and Procedures Used in IT-15 Gene Analysis
Individual laboratories are responsible for meeting the
CLIA/CAP quality control standards for molecular di-
agnostic laboratories (American College of Medical Ge-
netics 1993). This includes, but is not limited to, ap-
propriate sample documentation, assay validation,
proficiency testing, and general quality control. Fur-
thermore, because of the sensitive and disclosing nature
of this type of testing, each laboratory should document
that informed consent was obtained for both diagnostic
(Beresford et al. 1996) and predictive (Guidelines for the
Molecular Genetics Predictive Test in Huntington’s Dis-
ease 1994) testing before IT-15 gene analysis is initiated.
Finally, clinicians and laboratories alike must remember
that the relevance of a predictive test result to an indi-
vidual is crucially dependent on the correct diagnosis of
HD in the family; whenever possible, the diagnosis
should be confirmed by molecular studies in an affected
individual before a molecular predictive test is per-
formed. The working group has the following additional
comments about laboratory procedures:
1. The Use of Primers that Distinguish the CAG from
the Adjacent CCG Repeat.—The CCG repeat that is ad-
jacent to the CAG repeat is polymorphic, with allele sizes
of 7–12 repeats. Use of primers that amplify both the
CAG repeat and the CCG repeat sequences can therefore
lead to diagnostic inaccuracy in the threshold CAG-re-
peat range (35–40 repeats) (Andrew et al. 1994). Thus,
primers that amplify the CAG-repeat sequence only, and
not the adjacent CCG repeat, should be a requirement
of all laboratories that perform IT-15 gene analysis for
clinical purposes.
2. Size Standards to be Used in Counting CAG-Repeat
Numbers.—The results of an IT-15 gene test are quan-
titative (i.e., counting repeat numbers), and a standard-
ized method of sizing alleles is required. Laboratories
should be particularly sensitive to the need for accuracy
in the critical range of 27–40 repeats, where a counting
error could lead to a categorical misinterpretation of the
results. Nondenaturing assays (i.e., agarose gels with
ethidium bromide staining) should not be used. As a
minimum, internal or external sequencing standards
should be selected that allow exact determination of the
size of the PCR product. These standards include (but
are not limited to) an M13 sequencing ladder and ap-
propriate normal and abnormal controls whose sizes
have been verified independently in a second laboratory
or laboratories. Ideally, cloned universal standards (e.g.,
a CAG 27 and a CAG 40) should be developed for
distribution to all laboratories, but these are not cur-
rently available commercially. Laboratories should vol-
untarily participate in proficiency testing that includes
assay of HD samples.
3. The Use of Southern Blot or Other AlternativeMeth-
ods in IT-15 Gene Analysis.—Occasional samples may
yield a single (apparently homozygous) allele according
to the standard PCR-based CAG-only assay. Additional
laboratory methods may be needed to ensure that a sec-
ond allele of a different size is not present. These meth-
ods can include use of different PCR primer pairs, which
may allow expansion and detection of larger alleles
(Warner et al. 1993); use of a CCG  CAG primer pair,
which can resolve the alleles if the CCG repeat is poly-
morphic (Andrew et al. 1993); and use of Southern blots
to detect very large alleles (Guida et al. 1996). The work-
ing group recommends that each laboratory either con-
sider the use of additional methods to resolve all ap-
parently homozygous alleles or refer such samples to
another laboratory experienced in the use of additional
assay methods. Laboratory reports should describe the
methods that were used to resolve ambiguous or unusual
results.
4. Inclusion of CAG-Repeat Number in Test Re-
ports.—The written IT-15 gene test report should include
the CAG-repeat numbers of both alleles and an expla-
nation of the significance of these allele sizes to the pa-
tient (see section A).
D. Sample Ownership
It has been stressed in a number of recent publications
that ownership of DNA research samples resides with
the individual from whom the sample was taken, not
with the physician or laboratory. Although most of these
prior documents concern samples obtained for research,
we believe that federal legislation will soon extend this
principle to DNA samples obtained for diagnostic pur-
poses. It is strongly recommended that each laboratory
that performs any gene tests for Huntington disease de-
velop detailed consent forms that specifically address (1)
whether the donor permits the DNA sample to be stored
after completion of the test(s) ordered, (2) whether the
donor permits the sample to be tested in the future for
other diagnostically relevant genes without further con-
sent, and (3) under what circumstances a sample taken
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for diagnostic purposes may be used in research.Consent
forms should be required to accompany all samples prior
to testing.
The American College of Medical Genetics/
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